2024
Kidney Outcomes with GLP-1RAs, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk
Neumiller J, Herrin J, Swarna K, Polley E, Galindo R, Umpierrez G, Deng Y, Ross J, Mickelson M, McCoy R. Kidney Outcomes with GLP-1RAs, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk. Clinical Journal Of The American Society Of Nephrology 2024 DOI: 10.2215/cjn.0000000587.Peer-Reviewed Original ResearchSodium-glucose co-transporter 2 inhibitorsGlucagon-like peptide-1 receptor agonistsSodium-glucose co-transporter 2Dipeptidyl peptidase-4 inhibitorsGlucagon-like peptide-1Dipeptidyl peptidase-4Receptor agonistsPrimary composite outcomeKidney replacement therapyChronic kidney diseaseComposite outcomeSecondary composite outcomeType 2 diabetesGLP-1 receptor agonist therapyCVD riskCardiovascular diseaseModerate CVD riskPrescribed glucose-lowering agentsBaseline CVD riskHigh-risk patientsAssociated with risk reductionCKD stage 3Retrospective observational studyGlucose-lowering agentsModerate cardiovascular riskEffectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
McCoy R, Herrin J, Swarna K, Deng Y, Kent D, Ross J, Umpierrez G, Galindo R, Crown W, Borah B, Montori V, Brito J, Neumiller J, Mickelson M, Polley E. Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. Nature Cardiovascular Research 2024, 3: 431-440. PMID: 38846711, PMCID: PMC11156225, DOI: 10.1038/s44161-024-00453-9.Peer-Reviewed Original ResearchAdverse cardiovascular eventsGlucose-lowering medicationsType 2 diabetesCardiovascular diseaseGLP-1RACardiovascular eventsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsRetrospective cohort studyCardiovascular disease risk reductionGlucose-lowering agentsModerate cardiovascular riskCardiovascular risk reductionReceptor agonistsEffects of glucose-lowering medicationsRisk reductionCardiovascular riskCohort studyCardiovascular outcomesHigh riskBaseline riskModerate risk
2016
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. Diabetes Care 2016, 40: 468-475. PMID: 27659408, PMCID: PMC5360291, DOI: 10.2337/dc16-0985.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBlood GlucoseComorbidityDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug UtilizationFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinLogistic ModelsMaleMetforminMiddle AgedRetrospective StudiesSulfonylurea CompoundsThiazolidinedionesYoung AdultConceptsGlycemic controlSevere hypoglycemiaOlder patientsDipeptidyl peptidase-4 inhibitorsGlucose-lowering drugsGlucose-lowering medicationsProportion of patientsOverall glycemic controlPeptidase-4 inhibitorsMedicare Advantage patientsSex-standardized ratesType 2 diabetesOverall rateClass of agentsMore comorbiditiesChronic comorbiditiesYounger patientsAdvantage patientsDrug utilizationClaims dataPatientsHypoglycemiaHemoglobin AT2DMComorbidities